TY - JOUR
T1 - Progress toward personalized treatment of rheumatoid arthritis
AU - Keith, M. P.
AU - Edison, J. D.
AU - Gilliland, W. R.
PY - 2012/10
Y1 - 2012/10
N2 - Treatment of rheumatoid arthritis (RA) has advanced significantly over the past decade, in part because of the identification of key elements in the immunopathogenesis of the disease, leading to the development of targeted immune-based therapies. Despite the availability of many highly specific therapies, the process of selecting a treatment regimen for an individual patient remains empirical. Personalized treatment, focused on predicting efficacy, non-response, and toxicity to better guide medication selection, moves closer to realization as genomic methods continue to be extended and refined.
AB - Treatment of rheumatoid arthritis (RA) has advanced significantly over the past decade, in part because of the identification of key elements in the immunopathogenesis of the disease, leading to the development of targeted immune-based therapies. Despite the availability of many highly specific therapies, the process of selecting a treatment regimen for an individual patient remains empirical. Personalized treatment, focused on predicting efficacy, non-response, and toxicity to better guide medication selection, moves closer to realization as genomic methods continue to be extended and refined.
UR - http://www.scopus.com/inward/record.url?scp=84866614151&partnerID=8YFLogxK
U2 - 10.1038/clpt.2012.124
DO - 10.1038/clpt.2012.124
M3 - Article
C2 - 22910444
AN - SCOPUS:84866614151
SN - 0009-9236
VL - 92
SP - 440
EP - 442
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
IS - 4
ER -